

## Supplementary Online Content

Weintraub D, Chen P, Ignacio RV, Mamikonyan E, Kales HC. Patterns and trends in antipsychotic prescribing for Parkinson disease. *Arch Neurol.* 2011;68(7):899-904.

### **eTable. Changes Over 6-Year Period in Antipsychotic Prescribing (FY2002-FY2008)**

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable. Changes Over 6-Year Period in Antipsychotic Prescribing (FY2002-FY2008)**

Antipsychotic Prescribing	FY2002			FY2008		
	PD Group		Non-PD Dementia Group, No. (%) (n = 10 462)	PD Group		Non-PD Dementia Group, No. (%) (n = 6611)
	With Dementia, No. (%) (n = 1216)	Without Dementia, No. (%) (n = 1598)		With Dementia, No. (%) (n = 743)	Without Dementia, No. (%) (n = 1726)	
Any AP use	682 (56.1)	732 (45.8)	4854 (46.4)	420 (56.5)	801 (46.4)	3191 (48.3) <sup>a</sup>
Any typical AP	58 (4.8)	74 (4.6)	762 (7.3)	33 (4.4)	67 (3.9)	482 (7.3)
High potency	53 (4.4)	57 (3.6)	676 (6.5)	30 (4.0)	55 (3.2)	440 (6.7)
Any atypical AP	660 (54.3)	704 (44.1)	4507 (43.1)	407 (54.8)	768 (44.5)	2962 (44.8) <sup>a</sup>
Quetiapine	359 (29.5)	393 (24.6)	1108 (10.6)	285 (38.4) <sup>a</sup>	518 (30.0) <sup>a</sup>	1451 (22.0) <sup>a</sup>
Risperidone	229 (18.8)	208 (13.0)	2717 (26.0)	74 (10.0) <sup>b</sup>	141 (8.2) <sup>b</sup>	1236 (18.7) <sup>b</sup>
Aripiprazole	NA	NA	NA	39 (5.3)	111 (6.4)	260 (3.9)
Olanzapine	203 (16.7)	223 (14.0)	1370 (13.1)	53 (7.1) <sup>b</sup>	83 (4.8) <sup>b</sup>	435 (6.6) <sup>b</sup>
Ziprasidone	8 (0.7)	10 (0.6)	53 (0.5)	17 (2.3) <sup>a</sup>	31 (1.8) <sup>a</sup>	95 (1.4) <sup>a</sup>
Clozapine	5 (0.4)	8 (0.5)	9 (0.1)	5 (0.7)	14 (0.8)	4 (0.1)

Abbreviation: NA, not applicable.

<sup>a</sup> Significant increase between FY02 and FY08.

<sup>b</sup> Significant decrease between FY02 and FY08.